City Therapeutics (CTY) files S-1 for Nasdaq IPO with Goldman-led syndicate
As seen on the 24/7 Wall St. homepage on September 24, 2026.
City Therapeutics files for Nasdaq IPO with a four-bank syndicate led by Goldman Sachs
City Therapeutics has filed its S-1 to list on Nasdaq, with Goldman Sachs, Jefferies, Stifel and Oppenheimer running the books. Terms and deal size are not set yet, so the price range in the first amendment is the number that will define this one.
Continue ReadingShow less
City Therapeutics, Inc. has submitted its S-1 registration statement to the SEC, formally starting the clock on what would be a Nasdaq debut. The filing marks the transition from private company to public candidate, triggering the SEC review process that must conclude before shares can trade.
Goldman Sachs is leading the four-bank syndicate alongside Jefferies, Stifel, and Oppenheimer. That combination of a bulge-bracket lead with three active healthcare-focused underwriters signals the company is positioning for both institutional depth and sector-specialist coverage in the roadshow.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
No price range, share count, or deal size has been disclosed in this initial filing. Those terms will land in the first amendment to the S-1, and that document is the one that will define valuation expectations for prospective investors.
Until the amended filing arrives with a price range, the core due-diligence work for anyone tracking this offering is the S-1 itself, available through the SEC's EDGAR system, where the company's financials, risk factors, and business description are laid out in full.